BEGIN:VCALENDAR VERSION:2.0 PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4// BEGIN:VEVENT UID:20260728T174355EDT-1725BN4GWM@132.216.98.100 DTSTAMP:20260728T214355Z DESCRIPTION:Abstract\n\nThis thesis presents\, in sum\, the first image-bas ed longitudinal deep learning precision medicine model. The model uses mod ern deep learning methods and classical treatment effect estimation theory to estimate individual treatment effects (ITE) using high-dimensional pat ient MRI sequences as input. Before\, treatment effect analysis focused on differences across entire populations of treated patients or subgroups of patients with simple distinguishing factors\, e.g.\, sex. With unique pat ient data\, such as MRI sequences\, treatment effects can be estimated for the individual\, which offers a fine-grained estimate of patient response . Currently\, the models built using high-dimensional imaging data have on ly focused on predicting disease outcomes for only a single treatment. The se models help doctors manage patient risk\, but predicting a single outco me only is insufficient for treatment effect estimation. Treatment effect analysis takes a step beyond single outcome prediction by predicting outco mes for all potential therapies.\n\nTo achieve the goal of personalized tr eatment predictions\, we developed the first imaging-based precision medic ine model. The model is trained on data spanning different stages of multi ple sclerosis (MS) and has been designed to predict several clinically rel evant outcomes. Our first advancement estimates the number of future brain lesions for the Relapsing Remitting form of MS (RRMS) on five treatments and placebo. We demonstrate accurate prediction when the model makes a pre diction for the patient's assigned therapy (factual outcome) and on the id entification of groups that have heterogeneous responses to treatment. We deem such patients responders. In some cases\, we found subgroups of respo nders whose outcomes were statistically significantly improved\, even for drugs that did not have significant effects at the group level.\n\nOur nex t advancement better aids clinical decision-making by quantifying and vali dating the uncertainty in predictions of treatment effect. Uncertainty qua ntification is critical in high-risk applications\, such as treatment reco mmendation\, as time spent on non-working treatments can have long-lasting irreparable effects. We show that treatment recommendations made with add itional uncertainty information improves decision-making and leads to bett er outcomes when treating a population of patients.\n\nThe final contribut ion models the disease trajectory over time. Modeling the trajectory of pa tients becomes far more important when considering longitudinal diseases\, where the intermediate outcomes can be just as important as the outcomes at the end. As MS is a chronic disease\, predicting the entire trajectory better estimates the patient's experience throughout the disease. We valid ate these predictions on new lesion development and an outcome that better reflects the patient's quality of life\, the Expanded Disability Status S cale (EDSS). The EDSS is more difficult to predict as it is not an image-b ased measure of MS\; however\, it is the primary outcome of interest in th e Second Progressive (SPMS) and Primary Progressive (PPMS) subtypes of MS. Finally\, it should be noted that while this work focuses on multiple scl erosis outcomes\, the framework and design considerations can be applied b roadly for any personalized medicine tools built using complex data.\n DTSTART:20250314T140000Z DTEND:20250314T160000Z LOCATION:Room 603\, McConnell Engineering Building\, CA\, QC\, Montreal\, H 3A 0E9\, 3480 rue University SUMMARY:PhD defence of Joshua Durso-Finley – Uncertainty Aware Causal Model s for Prediction of Individual Treatment Effects for Image-based Precision Medicine URL:/ece/channels/event/phd-defence-joshua-durso-finle y-uncertainty-aware-causal-models-prediction-individual-treatment-363950 END:VEVENT END:VCALENDAR